As more health insurers move to cover policy holders on a budgeted basis in Massachusetts’ hospitals, healthcare systems have come to question the viability of expensive procedures that offer little to no benefits. Working under a bundled payment arrangement, the less hospitals can perform unnecessary, costly procedures for patients, the more apt hospitals are to drive revenue and improve care quality.
“The majority of women diagnosed with ductal carcinoma in situ will not develop invasive cancer, meaning that many women are currently being treated with minimal to no potential benefits,” said Ann Partridge, MD, a senior physician in the Susan F. Smith Center for Women’s Cancers at Dana-Farber and the study’s co-principal leader, according to Boston Business Journal.
In the study, conducted with the help of researchers from DukeMedicalCenter in Durham, N.C., and MD Anderson Cancer Center in Houston, patients diagnosed with DCIS will be randomly assigned to either a group receiving current standards of treatment (including surgery and/or radiation) or a surveillance group. The trial will enroll 900 patients.
Researchers said they hope to study if the incidence of cancer, survival and mastectomy rates and quality of life differ between the two groups, reports Boston Business Journal.
Ductal carcinoma in situ is the most common type of non-invasive breast cancer, with about 60,000 cases diagnosed in the U.S. each year, according to the American Cancer Society.
More articles on finance issues:
Cumberland Consulting launches performance improvement, revenue cycle arm
MedKoder to launch apprenticeship program for aspiring medical coders
Survey reveals how patients shoulder burden of fragmented healthcare system
